Colon cancer has undergone significant changes and has seen increasing treatment options. With more and more drugs available and approved for colon cancer we are facing difficult decisions deciding what is the right treatment at the right time.
For patients with newly diagnosed colon cancer we have two chemotherapeutic regimens: a combination of infusional 5-FU with irinotecan (FOLFIRI) or with oxaliplatin (FOLFOX). Both regimens have shown similar efficacy and similar extent of toxicity however there are differences in the quality of toxicity. More often FOLFOX has to be stopped because of its neurotoxicity than because it stopped working. Read the rest of this entry »